Total Payments
$402,512
2024 Payments
$15,272
Companies
99
Transactions
1,830
Medicare Patients
19,582
Medicare Billing
$6.2M
Payment Breakdown by Category
Other$205,555 (51.1%)
Consulting$77,950 (19.4%)
Travel$44,896 (11.2%)
Food & Beverage$37,511 (9.3%)
Research$35,839 (8.9%)
Education$760.52 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $198,150 | 97 | 49.2% |
| Consulting Fee | $77,950 | 38 | 19.4% |
| Travel and Lodging | $44,896 | 98 | 11.2% |
| Food and Beverage | $37,511 | 1,544 | 9.3% |
| Unspecified | $35,839 | 24 | 8.9% |
| Honoraria | $7,405 | 7 | 1.8% |
| Education | $760.52 | 22 | 0.2% |
Payments by Type
General
$366,673
1,806 transactions
Research
$35,839
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $135,294 | 162 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $71,647 | 211 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25,053 | 31 | $0 (2023) |
| Genentech USA, Inc. | $24,561 | 97 | $0 (2024) |
| PFIZER INC. | $22,196 | 124 | $0 (2024) |
| F. Hoffmann-La Roche AG | $15,170 | 4 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $12,627 | 58 | $0 (2024) |
| Seagen Inc. | $10,300 | 53 | $0 (2023) |
| Merck Sharp & Dohme LLC | $9,445 | 111 | $0 (2024) |
| Janssen Biotech, Inc. | $8,197 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,272 | 212 | Novartis Pharmaceuticals Corporation ($11,008) |
| 2023 | $14,628 | 218 | Novartis Pharmaceuticals Corporation ($5,779) |
| 2022 | $7,178 | 189 | AstraZeneca Pharmaceuticals LP ($1,320) |
| 2021 | $11,269 | 137 | Novartis Pharmaceuticals Corporation ($2,947) |
| 2020 | $56,579 | 194 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,469) |
| 2019 | $160,086 | 322 | Lilly USA, LLC ($72,914) |
| 2018 | $106,874 | 332 | Lilly USA, LLC ($62,051) |
| 2017 | $30,625 | 226 | PFIZER INC. ($10,042) |
All Payment Transactions
1,830 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $92.55 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $53.26 | General |
| Category: ONC | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Immunology | ||||||
| 12/05/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $11.01 | General |
| Category: Oncology | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $35.95 | General |
| Category: Hematology | ||||||
| 11/26/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $31.46 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $36.06 | General |
| Category: Hematology | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $7.58 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nubeqa | Food and Beverage | In-kind items and services | $1.53 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Rare Disease | ||||||
| 11/13/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/12/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $29.35 | General |
| Category: Oncology | ||||||
| 11/12/2024 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $3.04 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.95 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CLEE011O12301C | Novartis Pharmaceuticals Corporation | $7,470 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,336 | 6 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| MONARCHER-A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIANS CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $3,251 | 1 |
| LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | Eli Lilly and Company | $2,782 | 3 |
| KISQALI Study Related Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $2,762 | 1 |
| RV-FOL-GELARC-0683C | Celgene Corporation | $2,244 | 1 |
| RV-FOL-GELARC-0683C - A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Ly | Celgene Corporation | $1,730 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $1,407 | 1 |
| CLEE011A2301,CLEE011E2301,CLEE011F2301 | Novartis Pharmaceuticals Corporation | $939.31 | 1 |
| TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK 4 AND OR 6 INHIBITOR | Novartis Pharmaceuticals Corporation | $686.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $631.79 | 2 |
| Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | Seattle Genetics, Inc. | $119.22 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 3,005 | 73,615 | $3.1M | $926,442 |
| 2022 | 57 | 4,359 | 81,653 | $4.2M | $1.3M |
| 2021 | 66 | 5,802 | 103,054 | $5.3M | $1.7M |
| 2020 | 74 | 6,416 | 133,502 | $6.8M | $2.2M |
Total Patients
19,582
Total Services
391,824
Medicare Billing
$6.2M
Procedure Codes
237
All Medicare Procedures & Services
237 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 19 | 13,000 | $1.8M | $562,313 | 31.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 46 | 5,940 | $302,940 | $107,935 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 240 | 642 | $215,654 | $61,733 | 28.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 403 | 724 | $165,710 | $46,904 | 28.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 81 | 287 | $108,486 | $29,567 | 27.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 28 | 4,260 | $97,980 | $25,167 | 25.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 569 | 1,524 | $44,196 | $11,544 | 26.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 544 | 1,332 | $11,988 | $11,189 | 93.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 18 | 7,670 | $38,350 | $10,520 | 27.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 22 | 16,320 | $65,280 | $6,547 | 10.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 66 | 119 | $22,491 | $5,928 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $18,594 | $4,903 | 26.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 159 | 417 | $28,773 | $4,578 | 15.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 68 | 377 | $22,997 | $4,549 | 19.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 79 | $14,062 | $4,095 | 29.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $12,480 | $3,692 | 29.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 99 | $8,316 | $2,282 | 27.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 46 | $9,476 | $2,279 | 24.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 15 | $6,939 | $2,141 | 30.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 46 | 82 | $12,792 | $2,069 | 16.2% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 18 | 13,200 | $26,400 | $2,049 | 7.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 79 | $6,241 | $1,789 | 28.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 27 | $5,319 | $1,748 | 32.9% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 64 | $5,696 | $1,607 | 28.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $6,116 | $1,561 | 25.5% |
About Dr. Lowell Hart, M.D
Dr. Lowell Hart, M.D is a Medical Oncology healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245221993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lowell Hart, M.D has received a total of $402,512 in payments from pharmaceutical and medical device companies, with $15,272 received in 2024. These payments were reported across 1,830 transactions from 99 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($198,150).
As a Medicare-enrolled provider, Hart has provided services to 19,582 Medicare beneficiaries, totaling 391,824 services with total Medicare billing of $6.2M. Data is available for 4 years (2020–2023), covering 237 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology
- Location Fort Myers, FL
- Active Since 11/02/2005
- Last Updated 02/03/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1245221993
Products in Payments
- VERZENIO (Drug) $120,052
- KISQALI (Drug) $43,920
- GILOTRIF (Drug) $25,053
- IBRANCE (Drug) $15,819
- TECENTRIQ (Biological) $15,283
- PIQRAY (Drug) $13,243
- Herceptin (Biological) $13,017
- Kadcyla (Biological) $9,886
- IMBRUVICA (Drug) $7,874
- XTANDI (Drug) $5,536
- AFINITOR (Drug) $4,659
- Enhertu (Drug) $4,491
- ZOLADEX (Drug) $4,298
- EMPLICITI (Biological) $4,260
- Revlimid (Drug) $4,176
- ZEJULA (Drug) $2,541
- VARUBI (Drug) $2,296
- XPOVIO (Drug) $2,287
- TYKERB (Drug) $2,188
- Imbruvica (Drug) $2,136
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Fort Myers
Dr. James Reeves, M.d, M.D
Medical Oncology — Payments: $198,428
Medical Oncology $198,428
Dr. Michael Mccleod, Do, DO
Medical Oncology — Payments: $63,904
Medical Oncology $63,904
Dr. Vitor Pastorini Filho, M.d, M.D
Medical Oncology — Payments: $18,036
Medical Oncology $18,036
Dr. Van Rana, 09221980, 09221980
Medical Oncology — Payments: $9,740
Medical Oncology $9,740
Venkata Parsa, Md, MD
Medical Oncology — Payments: $1,888
Medical Oncology $1,888
Dr. Manoel Moraes, Md, MD
Medical Oncology — Payments: $1,670
Medical Oncology $1,670